We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Faron Pharmaceuticals Oy | LSE:FARN | London | Ordinary Share | FI4000153309 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 150.00 | 140.00 | 160.00 | 150.00 | 150.00 | 150.00 | 4,213 | 07:44:03 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -28.73M | -0.4177 | -3.59 | 103.18M |
Date | Subject | Author | Discuss |
---|---|---|---|
18/3/2024 14:20 | Positive interview on Proactive. | pdt | |
18/3/2024 12:20 | I don't usually gamble but decided to make a small punt on today's news. It should be sufficient to enable them to get the £30m funding they need which in turn will enable them to get more results later in the year and successfully out licence. Result being a share price a multiple of todays. Alternatively they will fail to get funding or have future poor trial outcomes and I will lose 100% of today's punt. Either way on a 12 month time horizon I should know one way or the other. | pdt | |
04/3/2024 08:38 | Guess today's news leaked. | babbler | |
01/3/2024 19:16 | any reason for the rise today | latifs100 | |
21/2/2024 14:29 | Money moving to APH [LSE] , excellent growing health care company | blackhorse23 | |
19/2/2024 14:34 | Not exactly out of the blue if you had read the IPF financing terms and the convenants involved. It was obvious Faron would need more funding, whether they couldn't raise it by a placing or by other means I don't know, but I'm just glad I sold out last October before the last placing as I could see the cash flow problem. | 1347 | |
30/1/2024 08:10 | Money moving to APH | blackhorse23 | |
11/12/2023 07:18 | Stonking update thjs morning from Faron - we are on the cusp of a wave. | raldo | |
04/8/2023 23:32 | Starting to wake up at last, looking good for a further rise, lots of positive news released with more due! | soulected | |
16/1/2023 11:04 | From a 25% 5 year survival to 2 out of 3 previously refractory to other treatments, and now with reduction of blasts........this is a game changer, especially in myelodysplastic syndrome. | mcbull | |
16/1/2023 09:24 | More great progress, this is very promising!BEXMAB Study Update -- Objective response observed in 3 out of 5 patients in the first doublet cohort -- 2 of the 3 responders were refractory to prior azacitidine monotherapy -- No additional adverse events observed adding bexmarilimab to standard of care -- Rapid enrollment into both doublet and triplet combinations | soulected | |
07/12/2022 09:01 | What's moving it this morning? | soulected | |
05/12/2022 10:20 | Another step in (what appears to be) the right direction. Next year could be very interesting, especially if more centres come forward. Are there any known manufacturing, or distribution, limitations of Bexmab at the moment? | hashertu | |
28/11/2022 13:32 | https://www.redeye.s | share23 | |
24/11/2022 07:06 | https://www.redeye.s | share23 | |
16/11/2022 12:17 | Yes, it is looking very good - about time! | soulected | |
16/11/2022 07:32 | A lovely quiet board, but things starting to happen in the background for Faron? | raldo | |
18/10/2022 19:39 | https://www.faron.co | share23 | |
15/6/2022 20:48 | I wonder if they now know who will respond to treatment before the drug is given. Also, if the response rate would be higher if given to less ill patients whose immune system can still be stimulated into action. Time will tell. Notwithstanding, with my limited understanding of the science, the results look impressive. | hashertu | |
25/4/2022 14:58 | New job ad from Faron. Director of Finance. According to job description: " The goal is to elevate and develop the processes to level accepted by the SEC in case of a potential US listing".Key responsibilities-Lea | share23 | |
23/4/2022 18:56 | Faron latest presentation. CFO mentions that they have hired new VP of investor relations to New York and that they are making Faron Wallstreet ready. Are they getting ready for an IPO to Nasdaq, New York? (around 4:00 minutes)Additionally CEO talks about potential licensing deal for Bexmarilimab and refers to other deals that have been made in the area which are billion-dollar milestone deals. CEO also says after mentioning the billion dollar deals: Happy to say there are number of companies discussing with us (around 19:00 minutes).Can't believe this company is so under the radar with so low share price.https://faron. | share23 | |
23/2/2022 12:29 | Worth adding here at these levels IMHO, and have done 😀. Looking forward to hearing the webcast. DL | davidlloyd |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions